fa PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions بیماری های دهان Oral Medicine پژوهشي Research <p> <strong>Objectives</strong></p><p>  PRAME (Preferentially Expressed Antigen in Melanoma) is a tumor-associated antigen recognized by immunocytes, and it induces cytotoxic T cell-mediated responses in melanoma. PRAME expression in tumors interferes with retinoic acid receptor (RAR) signaling thus promoting tumor progression. Here, we study PRAME expression in head and neck squamous cell carcinoma (HNSCC) to determine its potential clinical significance. </p><p> <strong>Materials and methods</strong></p><p>  PRAME expression in HNSCC was evaluated by immunohistochemistry in tissue microarrays of primary tumors (n=53), metastatic lymph nodes (n=8) and normal oral mucosa (n=11). Biopsies of dysplastic oral lesions (n=12) were also examined. PRAME expression levels in tissues were correlated with markers of poor prognosis in HNSCC. PRAME mRNA in HNSCC cell lines and in normal immortalized human keratinocytes (HaCaT cell line) was measured by qRT-PCR, and the protein expression by flow cytometry and western blots. </p><p> <strong>Results</strong> </p><p> PRAME was expressed in HNSCC cell lines and HNSCC lesions. PRAME expression in dysplastic mucosa was variable. No or only weak expression was found in normal cells or tissues. PRAME expression levels significantly correlated with the tumor grade, size, nodal involvement and the clinical status of HNSCC patients. </p><p> <strong>Conclusions</strong></p><p>  Elevated PRAME expression associates with clinicopathologic markers of poor outcome in HNSCC and might identify potential candidates with pre-cancerous lesions for chemoprevention with retinoids. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Oncology</p><p> <a href="http://www.oraloncology.com/article/S1368-8375(12)00265-5/abstract" target="_blank"><font color="#0000ff">Full Text</font></a></p> Head and neck cancer, PRAME overexpression, Larynx dysplasia, Oral mucosa, Immunohistochemistry, Clinical association 0 0 http://idai.ir/browse.php?a_code=A-10-32-2438&slc_lang=fa&sid=1 Miroslaw J. Szczepanski 100319475328460011559 100319475328460011559 Yes Department of Clinical Immunology, University of Medical Sciences, Poznan, Poland Albert B. DeLeo 100319475328460011560 100319475328460011560 No University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA Michał Łuczak 100319475328460011561 100319475328460011561 No Department of Biochemistry and Molecular Biology, University of Medical Sciences, Poznan, Poland Marta Molinska-Glura 100319475328460011562 100319475328460011562 No Department of Computer Science and Statistics, University of Medical Sciences, Poznan, Poland Jan Misiak 100319475328460011563 100319475328460011563 No Department of Clinical Immunology, University of Medical Sciences, Poznan, Poland Bronislawa Szarzynska 100319475328460011564 100319475328460011564 No Department of Clinical Immunology, University of Medical Sciences, Poznan, Poland Grzegorz Dworacki 100319475328460011565 100319475328460011565 No Department of Clinical Immunology, University of Medical Sciences, Poznan, Poland Mariola Zagor 100319475328460011566 100319475328460011566 No Department of Otolaryngology, Division of Dentistry, Medical University of Warsaw, Warsaw, Poland Natalia Rozwadowska 100319475328460011567 100319475328460011567 No Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland Theresa L. Whiteside 100319475328460011568 100319475328460011568 No University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA